Prime Medicine Inc (PRME)

$3.05 -0.12 (-3.79%)
Market Cap 574.97M
Revenue (ttm) 4.63M
Net Income (ttm) -201.14M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -4,344.28%
Debt to Equity Ratio 0.00
Volume 1,270,200
Avg Vol 3,300,282
Day's Range N/A - N/A
Shares Out 181.38M
Stochastic %K 35%
Beta 2.31
Analysts Strong Sell
Price Target $7.03

Company Profile

Prime Medicine, Inc., a biotechnology company, engages in delivering genetic medicines to address the spectrum of diseases by deploying gene editing technology in the United States. Its lead therapeutic product candidate is PM359 for Chronic Granulomatous Disease, which is in Phase 1/2 clinical trial; PM577 for Wilson Disease, that is in preclinical studies; and PM647 to treat genetic disorder caused by mutations in the SERPINA1 gene, resulting in production of misfolded Z-AAT protein that accum...

Industry: Biotechnology
Sector: Healthcare
Phone: 617 465 0013
Address:
60 First Street, Cambridge, United States
USAEquityResearch
USAEquityResearch Aug. 18 at 10:32 PM
$PRME 📊 USAEquityResearch ▼ 3.05 (-3.79%) Trend: Bearish 📉 RSI (14): 50.8 — neutral territory MACD: bullish, above signal line and rising Volume: below average 📌 Key Levels Resistance: 3.26 Support: 2.81 20-MA: 3.05 | 50-MA: 3.26 Educational content only. Not financial advice.
0 · Reply
notreload_ai
notreload_ai Aug. 18 at 9:00 PM
BMO initiates $PRME at Outperform/$9, citing its unique prime-editing tech that delivers precise DNA fixes without double-strand breaks. https://notreload.xyz/xy/bmo-outperform-on-prme-for-differentiated-gene-editing/
1 · Reply
Toro_of_Ga
Toro_of_Ga Aug. 17 at 3:16 PM
$PRME lets go..
0 · Reply
Patrick0423
Patrick0423 Aug. 17 at 12:32 PM
$PRME How’s this? I heard someone recommend him at a high-end dinner.
1 · Reply
veryboredXYZ
veryboredXYZ Aug. 15 at 12:39 AM
$PRME buying zone, stay like that til Monday pls
0 · Reply
DOGBIRD
DOGBIRD Aug. 14 at 6:11 PM
$PRME Surprise us with a deal. Solve the cash concerns. It'll pop like a slingshot.
0 · Reply
AcceleratorModel
AcceleratorModel Aug. 14 at 4:28 PM
$PRME time cmon !
0 · Reply
PorkchopSquats
PorkchopSquats Aug. 14 at 2:22 PM
$PRME
0 · Reply
BIOTECH_GURU
BIOTECH_GURU Aug. 14 at 11:01 AM
$PRME They own patent for genetic editing technology that is proven on the benchtop and now has human data to support it. Best case scenario, adoption of multiple genetic conditions to include common diseases like hyperlipidemia with pcsk9 gene deletion, with no live failure signal. This would move from a rare disease TAM to a cardiovascular disease prevention/treatment TAM. This would become instantly $20B acquisition target. Worst case scenario: they get bought out for a cheap price prior to recognition of potention just like $VERV Timwline 12-24 months. Nfa. Gltya.
0 · Reply
DOGBIRD
DOGBIRD Aug. 13 at 4:39 PM
$PRME Curious if Optiprime will open more doors for deals near term.
0 · Reply
Latest News on PRME
BMO starts Prime Medicine at Outperform into 2027 readouts

2026-08-18T20:35:46.000Z - 16 hours ago

BMO starts Prime Medicine at Outperform into 2027 readouts

Prime Medicine initiated with an Outperform at BMO Capital

2026-08-18T20:25:25.000Z - 16 hours ago

Prime Medicine initiated with an Outperform at BMO Capital

Prime Medicine reports Q4 EPS (24c), consensus (26c)

2026-08-06T13:22:11.000Z - 12 days ago

Prime Medicine reports Q4 EPS (24c), consensus (26c)

Prime Medicine Quarterly report: Q2 2026

Aug 6, 2026, 7:00 AM EDT - 13 days ago

Prime Medicine Quarterly report: Q2 2026

Prime Medicine Earnings release: Q2 2026

Aug 6, 2026, 7:00 AM EDT - 13 days ago

Prime Medicine Earnings release: Q2 2026

Prime Medicine Announces U.S. FDA Clearance of Investigational New Drug Application for PM577a in H1069Q-mutated Wilson Disease

Jul 23, 2026, 4:05 PM EDT - 26 days ago

Prime Medicine Announces U.S. FDA Clearance of Investigational New Drug Application for PM577a in H1069Q-mutated Wilson Disease

TD Cowen says arbitration decision removes overhang for Prime Medicine’s PM647

2026-07-08T16:45:10.000Z - 5 weeks ago

TD Cowen says arbitration decision removes overhang for Prime Medicine’s PM647

BEAM

Resolution in favor of Prime has limited impact to Beam, says BofA

2026-07-08T15:45:15.000Z - 5 weeks ago

Resolution in favor of Prime has limited impact to Beam, says BofA

BEAM

Prime Medicine reports positive resolution to arbitration with Beam Therapeutics

2026-07-08T15:40:10.000Z - 5 weeks ago

Prime Medicine reports positive resolution to arbitration with Beam Therapeutics

BEAM

Prime Medicine Announces Positive Resolution to Arbitration with Beam Therapeutics

Jul 8, 2026, 8:00 AM EDT - 6 weeks ago

Prime Medicine Announces Positive Resolution to Arbitration with Beam Therapeutics

Cathie Wood’s ARK Investment buys 206.2K shares of Prime Medicine today

2026-07-08T00:15:14.000Z - 6 weeks ago

Cathie Wood’s ARK Investment buys 206.2K shares of Prime Medicine today

Prime Medicine Slides: Corporate presentation

Jul 7, 2026, 7:00 AM EDT - 6 weeks ago

Prime Medicine Slides: Corporate presentation

Prime Medicine upgraded to Buy from Neutral at H.C. Wainwright

2026-06-29T10:06:00.000Z - 7 weeks ago

Prime Medicine upgraded to Buy from Neutral at H.C. Wainwright

Prime Medicine granted RMAT designation for PM359

2026-06-22T12:20:45.000Z - 2 months ago

Prime Medicine granted RMAT designation for PM359

Prime Medicine Receives U.S. FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for PM359 for the Treatment of Chronic Granulomatous Disease (CGD)

Jun 22, 2026, 8:00 AM EDT - 2 months ago

Prime Medicine Receives U.S. FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for PM359 for the Treatment of Chronic Granulomatous Disease (CGD)

Prime Medicine announces New Zealand cleared trial application for PM577a

2026-06-18T12:13:20.000Z - 2 months ago

Prime Medicine announces New Zealand cleared trial application for PM577a

Prime Medicine Announces New Zealand Clearance of Clinical Trial Application for PM577a in H1069Q-mutated Wilson Disease

Jun 18, 2026, 8:00 AM EDT - 2 months ago

Prime Medicine Announces New Zealand Clearance of Clinical Trial Application for PM577a in H1069Q-mutated Wilson Disease

Prime Medicine Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026

Jun 10, 2026, 10:40 AM EDT - 2 months ago

Prime Medicine Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026

Prime Medicine Transcript: AGM 2026

Jun 5, 2026, 2:00 PM EDT - 2 months ago

Prime Medicine Transcript: AGM 2026

Prime Medicine Transcript: Jefferies Global Healthcare Conference 2026

Jun 4, 2026, 12:50 PM EDT - 2 months ago

Prime Medicine Transcript: Jefferies Global Healthcare Conference 2026

Prime Medicine to Present at Goldman Sachs 47th Annual Global Healthcare Conference

Jun 3, 2026, 8:00 AM EDT - 2 months ago

Prime Medicine to Present at Goldman Sachs 47th Annual Global Healthcare Conference

Prime Medicine Slides: Corporate presentation

Jun 3, 2026, 7:00 AM EDT - 2 months ago

Prime Medicine Slides: Corporate presentation

Prime Medicine to Present at Jefferies Global Healthcare Conference

May 28, 2026, 8:00 AM EDT - 2 months ago

Prime Medicine to Present at Jefferies Global Healthcare Conference

Prime Medicine reports Q1 EPS (28c), consensus (25c)

2026-05-07T19:46:03.000Z - 3 months ago

Prime Medicine reports Q1 EPS (28c), consensus (25c)

Prime Medicine Reports First Quarter 2026 Financial Results and Provides Business Updates

May 7, 2026, 8:00 AM EDT - 3 months ago

Prime Medicine Reports First Quarter 2026 Financial Results and Provides Business Updates

Prime Medicine Quarterly report: Q1 2026

May 7, 2026, 7:00 AM EDT - 3 months ago

Prime Medicine Quarterly report: Q1 2026

Prime Medicine Earnings release: Q1 2026

May 7, 2026, 7:00 AM EDT - 3 months ago

Prime Medicine Earnings release: Q1 2026

Prime Medicine management to meet with Oppenheimer

2026-05-07T02:02:00.000Z - 3 months ago

Prime Medicine management to meet with Oppenheimer

Prime Medicine Proxy statement: Proxy filing

Apr 23, 2026, 8:00 AM EDT - 4 months ago

Prime Medicine Proxy statement: Proxy filing

Prime Medicine Proxy statement: Proxy filing

Apr 23, 2026, 8:00 AM EDT - 4 months ago

Prime Medicine Proxy statement: Proxy filing

Prime Medicine appoints Makhni as Chief Financial Officer

2026-04-16T12:25:29.000Z - 4 months ago

Prime Medicine appoints Makhni as Chief Financial Officer

Prime Medicine Appoints Svetlana Makhni as Chief Financial Officer

Apr 16, 2026, 8:00 AM EDT - 4 months ago

Prime Medicine Appoints Svetlana Makhni as Chief Financial Officer

Oppenheimer bullish on Prime Medicine, initiates with an Outperform

2026-03-12T11:46:56.000Z - 5 months ago

Oppenheimer bullish on Prime Medicine, initiates with an Outperform

Prime Medicine initiated with an Outperform at Oppenheimer

2026-03-12T10:26:58.000Z - 5 months ago

Prime Medicine initiated with an Outperform at Oppenheimer

Prime Medicine Transcript: The Citizens Life Sciences Conference 2026

Mar 11, 2026, 2:15 PM EDT - 5 months ago

Prime Medicine Transcript: The Citizens Life Sciences Conference 2026

Prime Medicine Transcript: TD Cowen 46th Annual Health Care Conference

Mar 4, 2026, 1:10 PM EST - 5 months ago

Prime Medicine Transcript: TD Cowen 46th Annual Health Care Conference

Prime Medicine reports FY25 EPS ($1.35) vs ($1.65) last year

2026-03-03T13:07:13.000Z - 6 months ago

Prime Medicine reports FY25 EPS ($1.35) vs ($1.65) last year

Prime Medicine Reports Full Year 2025 Financial Results and Provides Business Updates

Mar 3, 2026, 8:00 AM EST - 6 months ago

Prime Medicine Reports Full Year 2025 Financial Results and Provides Business Updates

Prime Medicine Annual report: Q4 2025

Mar 3, 2026, 8:00 AM EST - 6 months ago

Prime Medicine Annual report: Q4 2025

Prime Medicine Earnings release: Q4 2025

Mar 3, 2026, 8:00 AM EST - 6 months ago

Prime Medicine Earnings release: Q4 2025

Prime Medicine Slides: Corporate presentation

Mar 2, 2026, 7:00 AM EST - 6 months ago

Prime Medicine Slides: Corporate presentation

Prime Medicine to Participate in Upcoming Investor Conferences

Feb 25, 2026, 8:00 AM EST - 6 months ago

Prime Medicine to Participate in Upcoming Investor Conferences

Prime Medicine Transcript: 44th Annual J.P. Morgan Healthcare Conference

Jan 14, 2026, 12:00 PM EST - 7 months ago

Prime Medicine Transcript: 44th Annual J.P. Morgan Healthcare Conference

Prime Medicine Slides: 44th Annual J.P. Morgan Healthcare Conference

Jan 14, 2026, 12:00 PM EST - 7 months ago

Prime Medicine Slides: 44th Annual J.P. Morgan Healthcare Conference

Prime Medicine to Present at 44th Annual J.P. Morgan Healthcare Conference

Jan 7, 2026, 8:00 AM EST - 7 months ago

Prime Medicine to Present at 44th Annual J.P. Morgan Healthcare Conference

Prime Medicine initiated with an Outperform at LifeSci Capital

2025-12-23T13:50:25.000Z - 8 months ago

Prime Medicine initiated with an Outperform at LifeSci Capital

Prime Medicine announces NEJM publication of PM359 data

2025-12-07T18:30:05.000Z - 9 months ago

Prime Medicine announces NEJM publication of PM359 data

Prime Medicine Announces The New England Journal of Medicine Publication of PM359 Clinical Data for the Treatment of Chronic Granulomatous Disease

Dec 7, 2025, 8:05 AM EST - 9 months ago

Prime Medicine Announces The New England Journal of Medicine Publication of PM359 Clinical Data for the Treatment of Chronic Granulomatous Disease

Prime Medicine Transcript: Evercore ISI 8th Annual HealthCONx Conference

Dec 2, 2025, 11:15 AM EST - 9 months ago

Prime Medicine Transcript: Evercore ISI 8th Annual HealthCONx Conference

Prime Medicine to Present at 8th Annual Evercore Healthcare Conference

Nov 25, 2025, 8:00 AM EST - 9 months ago

Prime Medicine to Present at 8th Annual Evercore Healthcare Conference

Prime Medicine Transcript: Jefferies London Healthcare Conference 2025

Nov 18, 2025, 7:00 AM EST - 9 months ago

Prime Medicine Transcript: Jefferies London Healthcare Conference 2025

Prime Medicine Transcript: KOL Event

Nov 12, 2025, 8:00 AM EST - 9 months ago

Prime Medicine Transcript: KOL Event

Prime Medicine Press release: KOL Event

Nov 12, 2025, 8:00 AM EST - 9 months ago

Prime Medicine Press release: KOL Event

Prime Medicine Slides: KOL Event

Nov 12, 2025, 8:00 AM EST - 9 months ago

Prime Medicine Slides: KOL Event

CORRECTION - Prime Medicine Reports Third Quarter 2025 Financial Results and Provides Business Updates

Nov 7, 2025, 10:21 AM EST - 10 months ago

CORRECTION - Prime Medicine Reports Third Quarter 2025 Financial Results and Provides Business Updates

Prime Medicine Reports Third Quarter 2025 Financial Results and Provides Business Updates

Nov 7, 2025, 7:00 AM EST - 10 months ago

Prime Medicine Reports Third Quarter 2025 Financial Results and Provides Business Updates

Prime Medicine Quarterly report: Q3 2025

Nov 7, 2025, 7:00 AM EST - 10 months ago

Prime Medicine Quarterly report: Q3 2025

Prime Medicine Earnings release: Q3 2025

Nov 7, 2025, 7:00 AM EST - 10 months ago

Prime Medicine Earnings release: Q3 2025

Prime Medicine Slides: Corporate Presentation

Nov 6, 2025, 7:00 AM EST - 10 months ago

Prime Medicine Slides: Corporate Presentation

Prime Medicine Appoints Matthew Hawryluk, Ph.D., M.B.A. as Chief Business Officer

Nov 3, 2025, 8:01 AM EST - 10 months ago

Prime Medicine Appoints Matthew Hawryluk, Ph.D., M.B.A. as Chief Business Officer

Prime Medicine to Host Virtual KOL Event to Showcase Wilson's Disease Strategy

Oct 30, 2025, 4:01 PM EDT - 10 months ago

Prime Medicine to Host Virtual KOL Event to Showcase Wilson's Disease Strategy

Prime Medicine Transcript: Chardan’s 9th Annual Genetic Medicines Conference

Oct 21, 2025, 8:45 AM EDT - 10 months ago

Prime Medicine Transcript: Chardan’s 9th Annual Genetic Medicines Conference

Prime Medicine Transcript: H. C. Wainwright Genetic Medicines Virtual Conference

Oct 14, 2025, 7:00 AM EDT - 11 months ago

Prime Medicine Transcript: H. C. Wainwright Genetic Medicines Virtual Conference

Prime Medicine Slides: Corporate Presentation

Sep 17, 2025, 7:00 AM EDT - 1 year ago

Prime Medicine Slides: Corporate Presentation

Prime Medicine Transcript: Morgan Stanley 23rd Annual Global Healthcare Conference

Sep 8, 2025, 1:05 PM EDT - 1 year ago

Prime Medicine Transcript: Morgan Stanley 23rd Annual Global Healthcare Conference

Prime Medicine Transcript: Citi's Biopharma Back to School Conference

Sep 2, 2025, 4:45 PM EDT - 1 year ago

Prime Medicine Transcript: Citi's Biopharma Back to School Conference

Prime Medicine Quarterly report: Q2 2025

Aug 7, 2025, 8:30 AM EDT - 1 year ago

Prime Medicine Quarterly report: Q2 2025

Prime Medicine Earnings release: Q2 2025

Aug 7, 2025, 8:30 AM EDT - 1 year ago

Prime Medicine Earnings release: Q2 2025

Prime Medicine Reports Second Quarter 2025 Financial Results and Provides Business Updates

Aug 7, 2025, 8:00 AM EDT - 1 year ago

Prime Medicine Reports Second Quarter 2025 Financial Results and Provides Business Updates

Prime Medicine Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares

Aug 1, 2025, 4:01 PM EDT - 1 year ago

Prime Medicine Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares

Prime Medicine Announces Pricing of Public Offering

Jul 30, 2025, 9:33 PM EDT - 1 year ago

Prime Medicine Announces Pricing of Public Offering

Prime Medicine Announces Proposed Public Offering of Common Stock

Jul 30, 2025, 4:01 PM EDT - 1 year ago

Prime Medicine Announces Proposed Public Offering of Common Stock

Cystic Fibrosis Foundation Commits Up to an Additional $24 Million for Prime Medicine to Develop Gene Editing Therapy

Jul 16, 2025, 8:10 AM EDT - 1 year ago

Cystic Fibrosis Foundation Commits Up to an Additional $24 Million for Prime Medicine to Develop Gene Editing Therapy

Prime Medicine Announces Additional Funding of Up to $24 Million from the Cystic Fibrosis Foundation to Advance Prime Editing Treatments for Cystic Fibrosis

Jul 16, 2025, 7:00 AM EDT - 1 year ago

Prime Medicine Announces Additional Funding of Up to $24 Million from the Cystic Fibrosis Foundation to Advance Prime Editing Treatments for Cystic Fibrosis

Prime Medicine Proxy statement: Proxy Filing

Jul 14, 2025, 8:00 AM EDT - 1 year ago

Prime Medicine Proxy statement: Proxy Filing

Prime Medicine Proxy statement: Proxy Filing

Jul 2, 2025, 8:00 AM EDT - 1 year ago

Prime Medicine Proxy statement: Proxy Filing

Prime Medicine Slides: Corporate Presentation

Jun 25, 2025, 7:00 AM EDT - 1 year ago

Prime Medicine Slides: Corporate Presentation

Prime Medicine Transcript: Jefferies Global Healthcare Conference 2025

Jun 5, 2025, 10:30 AM EDT - 1 year ago

Prime Medicine Transcript: Jefferies Global Healthcare Conference 2025

Prime Medicine Announces Strategic Restructuring to Focus on Opportunities in Large Genetic Liver Diseases, Cystic Fibrosis, and Partnered Programs Alongside CEO Leadership Transition

May 19, 2025, 8:31 AM EDT - 1 year ago

Prime Medicine Announces Strategic Restructuring to Focus on Opportunities in Large Genetic Liver Diseases, Cystic Fibrosis, and Partnered Programs Alongside CEO Leadership Transition

Prime Medicine Announces Breakthrough Clinical Data Showing Rapid Restoration of DHR Positivity After Single Infusion of PM359, an Investigational Prime Editor for Chronic Granulomatous Disease

May 19, 2025, 8:30 AM EDT - 1 year ago

Prime Medicine Announces Breakthrough Clinical Data Showing Rapid Restoration of DHR Positivity After Single Infusion of PM359, an Investigational Prime Editor for Chronic Granulomatous Disease

Prime Medicine Proxy statement: Proxy Filing

May 19, 2025, 8:00 AM EDT - 1 year ago

Prime Medicine Proxy statement: Proxy Filing

Prime Medicine Reports First Quarter 2025 Financial Results and Provides Business Updates

May 8, 2025, 8:00 AM EDT - 1 year ago

Prime Medicine Reports First Quarter 2025 Financial Results and Provides Business Updates

Prime Medicine Quarterly report: Q1 2025

May 8, 2025, 7:00 AM EDT - 1 year ago

Prime Medicine Quarterly report: Q1 2025

Prime Medicine Earnings release: Q1 2025

May 8, 2025, 7:00 AM EDT - 1 year ago

Prime Medicine Earnings release: Q1 2025

Prime Medicine Proxy statement: Proxy Filing

Apr 22, 2025, 8:00 AM EDT - 1 year ago

Prime Medicine Proxy statement: Proxy Filing

Prime Medicine Proxy statement: Proxy Filing

Apr 22, 2025, 8:00 AM EDT - 1 year ago

Prime Medicine Proxy statement: Proxy Filing

Prime Medicine Unveils Program for the Treatment of Alpha-1 Antitrypsin Deficiency (AATD)

Mar 18, 2025, 7:00 AM EDT - 1 year ago

Prime Medicine Unveils Program for the Treatment of Alpha-1 Antitrypsin Deficiency (AATD)

Prime Medicine Transcript: TD Cowen 45th Annual Healthcare Conference

Mar 3, 2025, 11:10 AM EST - 1 year ago

Prime Medicine Transcript: TD Cowen 45th Annual Healthcare Conference

Prime Medicine Reports Full Year 2024 Financial Results and Provides Business Updates

Feb 28, 2025, 8:00 AM EST - 1 year ago

Prime Medicine Reports Full Year 2024 Financial Results and Provides Business Updates

Prime Medicine Annual report: Q4 2024

Feb 28, 2025, 8:00 AM EST - 1 year ago

Prime Medicine Annual report: Q4 2024

Prime Medicine Earnings release: Q4 2024

Feb 28, 2025, 8:00 AM EST - 1 year ago

Prime Medicine Earnings release: Q4 2024

Prime Medicine to Present at TD Cowen 45th Annual Health Care Conference

Feb 24, 2025, 8:00 AM EST - 1 year ago

Prime Medicine to Present at TD Cowen 45th Annual Health Care Conference

Kuehn Law Encourages Investors of Prime Medicine, Inc. to Contact Law Firm

Jan 30, 2025, 12:26 PM EST - 1 year ago

Kuehn Law Encourages Investors of Prime Medicine, Inc. to Contact Law Firm

Prime Medicine Transcript: 43rd Annual J.P. Morgan Healthcare Conference 2025

Jan 14, 2025, 6:00 PM EST - 1 year ago

Prime Medicine Transcript: 43rd Annual J.P. Morgan Healthcare Conference 2025

Prime Medicine Slides: FY 2025

Jan 14, 2025, 6:00 PM EST - 1 year ago

Prime Medicine Slides: FY 2025

Prime Medicine Registration statement: Registration Filing

Dec 13, 2024, 7:00 AM EST - 1 year ago

Prime Medicine Registration statement: Registration Filing

Wilson Disease Pipeline Market Research Report 2024: Comprehensive Insights on 5+ Drugs Featuring Vivet Therapeutics, Depymed, Prime Medicine, and Deep Genomics

Nov 21, 2024, 4:18 AM EST - 1 year ago

Wilson Disease Pipeline Market Research Report 2024: Comprehensive Insights on 5+ Drugs Featuring Vivet Therapeutics, Depymed, Prime Medicine, and Deep Genomics

Prime Medicine Transcript: Jefferies London Healthcare Conference 2024

Nov 19, 2024, 9:30 AM EST - 1 year ago

Prime Medicine Transcript: Jefferies London Healthcare Conference 2024

Prime Medicine Transcript: Stifel 2024 Healthcare Conference

Nov 18, 2024, 1:15 PM EST - 1 year ago

Prime Medicine Transcript: Stifel 2024 Healthcare Conference

Prime Medicine Transcript: Guggenheim Securities Inaugural Healthcare Innovation Conference

Nov 13, 2024, 3:00 PM EST - 1 year ago

Prime Medicine Transcript: Guggenheim Securities Inaugural Healthcare Innovation Conference

Prime Medicine Quarterly report: Q3 2024

Nov 12, 2024, 9:30 AM EST - 1 year ago

Prime Medicine Quarterly report: Q3 2024

Prime Medicine Earnings release: Q3 2024

Nov 12, 2024, 9:30 AM EST - 1 year ago

Prime Medicine Earnings release: Q3 2024

Prime Medicine Presents In Vivo Proof-of-Concept Data Highlighting Interim Preclinical Advances in its Wilson's Disease Program and the Broad Potential of its Universal Liver-Targeted LNP at ESGCT 31st Annual Congress

Oct 24, 2024, 8:00 AM EDT - 1 year ago

Prime Medicine Presents In Vivo Proof-of-Concept Data Highlighting Interim Preclinical Advances in its Wilson's Disease Program and the Broad Potential of its Universal Liver-Targeted LNP at ESGCT 31st Annual Congress

Prime Medicine to Highlight New Preclinical Data, Including In Vivo Data in Wilson's Disease, at Upcoming Scientific Meetings

Oct 15, 2024, 8:00 AM EDT - 2 years ago

Prime Medicine to Highlight New Preclinical Data, Including In Vivo Data in Wilson's Disease, at Upcoming Scientific Meetings

Prime Medicine Transcript: Chardan 8th Annual Genetic Medicines Conference

Sep 30, 2024, 1:30 PM EDT - 2 years ago

Prime Medicine Transcript: Chardan 8th Annual Genetic Medicines Conference

Prime Medicine Unveils Strategically Focused Pipeline

Sep 30, 2024, 7:01 AM EDT - 2 years ago

Prime Medicine Unveils Strategically Focused Pipeline

Prime Medicine Transcript: Morgan Stanley 22nd Annual Global Healthcare Conference

Sep 4, 2024, 1:05 PM EDT - 2 years ago

Prime Medicine Transcript: Morgan Stanley 22nd Annual Global Healthcare Conference

Prime Medicine Quarterly report: Q2 2024

Aug 8, 2024, 8:15 AM EDT - 2 years ago

Prime Medicine Quarterly report: Q2 2024

Prime Medicine Earnings release: Q2 2024

Aug 8, 2024, 8:15 AM EDT - 2 years ago

Prime Medicine Earnings release: Q2 2024

Prime Medicine Transcript: Goldman Sachs 45th Annual Global Healthcare Conference

Jun 10, 2024, 2:00 PM EDT - 2 years ago

Prime Medicine Transcript: Goldman Sachs 45th Annual Global Healthcare Conference

Prime Medicine Transcript: Jefferies 2024 Global Healthcare Conference

Jun 5, 2024, 1:30 PM EDT - 2 years ago

Prime Medicine Transcript: Jefferies 2024 Global Healthcare Conference

Prime Medicine Proxy statement: Proxy Filing

May 21, 2024, 8:00 AM EDT - 2 years ago

Prime Medicine Proxy statement: Proxy Filing

Prime Medicine Transcript: H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ

May 20, 2024, 4:30 PM EDT - 2 years ago

Prime Medicine Transcript: H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ

Prime Medicine to Present at H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ

May 13, 2024, 8:00 AM EDT - 2 years ago

Prime Medicine to Present at H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ

Alphabet Bought Up Two Slumping Stocks

May 12, 2024, 3:00 AM EDT - 2 years ago

Alphabet Bought Up Two Slumping Stocks

GOOG GOOGL GTLB

Prime Medicine Reports First Quarter 2024 Financial Results and Provides Business Updates

May 10, 2024, 8:00 AM EDT - 2 years ago

Prime Medicine Reports First Quarter 2024 Financial Results and Provides Business Updates

Prime Medicine Quarterly report: Q1 2024

May 10, 2024, 7:00 AM EDT - 2 years ago

Prime Medicine Quarterly report: Q1 2024

Prime Medicine Earnings release: Q1 2024

May 10, 2024, 7:00 AM EDT - 2 years ago

Prime Medicine Earnings release: Q1 2024

Prime Medicine Presents Preclinical Data Demonstrating Ability of PM359 to Efficiently, Reproducibly and Durably Correct Causative Mutation of Chronic Granulomatous Disease (CGD)

May 8, 2024, 8:00 AM EDT - 2 years ago

Prime Medicine Presents Preclinical Data Demonstrating Ability of PM359 to Efficiently, Reproducibly and Durably Correct Causative Mutation of Chronic Granulomatous Disease (CGD)

Prime Medicine Proxy statement: Proxy Filing

Apr 29, 2024, 8:00 AM EDT - 2 years ago

Prime Medicine Proxy statement: Proxy Filing

Prime Medicine Proxy statement: Proxy Filing

Apr 29, 2024, 8:00 AM EDT - 2 years ago

Prime Medicine Proxy statement: Proxy Filing

Prime Medicine Announces FDA Clearance of Investigational New Drug (IND) Application for PM359 for the Treatment of Chronic Granulomatous Disease (CGD)

Apr 29, 2024, 7:00 AM EDT - 2 years ago

Prime Medicine Announces FDA Clearance of Investigational New Drug (IND) Application for PM359 for the Treatment of Chronic Granulomatous Disease (CGD)

Prime Medicine to Present Preclinical Data Demonstrating Broad Potential of Prime Editing Technology at Upcoming Scientific Meetings

Apr 23, 2024, 8:00 AM EDT - 2 years ago

Prime Medicine to Present Preclinical Data Demonstrating Broad Potential of Prime Editing Technology at Upcoming Scientific Meetings

Prime Medicine Proxy statement: Proxy Filing

Apr 19, 2024, 8:00 AM EDT - 2 years ago

Prime Medicine Proxy statement: Proxy Filing

Prime Medicine Transcript: TD Cowen 44th Annual Health Care Conference 2024

Mar 6, 2024, 12:50 PM EST - 2 years ago

Prime Medicine Transcript: TD Cowen 44th Annual Health Care Conference 2024

Prime Medicine Reports Full Year 2023 Financial Results and Provides Business Updates

Mar 1, 2024, 8:00 AM EST - 2 years ago

Prime Medicine Reports Full Year 2023 Financial Results and Provides Business Updates

Prime Medicine Earnings release: Q4 2023

Mar 1, 2024, 7:00 AM EST - 2 years ago

Prime Medicine Earnings release: Q4 2023

Prime Medicine Annual report: Q4 2023

Mar 1, 2024, 7:00 AM EST - 2 years ago

Prime Medicine Annual report: Q4 2023

Prime Medicine Announces Closing of Upsized Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares

Feb 20, 2024, 4:01 PM EST - 2 years ago

Prime Medicine Announces Closing of Upsized Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares

Prime Medicine Announces Pricing of Upsized Public Offering

Feb 14, 2024, 11:50 PM EST - 2 years ago

Prime Medicine Announces Pricing of Upsized Public Offering

Prime Medicine Transcript: Guggenheim Healthcare Talks | 6th Annual Biotechnology Conference

Feb 8, 2024, 2:00 PM EST - 2 years ago

Prime Medicine Transcript: Guggenheim Healthcare Talks | 6th Annual Biotechnology Conference

Prime Medicine Receives Up to $15 Million from Cystic Fibrosis Foundation to Advance Hotspot and PASSIGE™ Prime Editors for Cystic Fibrosis

Jan 25, 2024, 8:00 AM EST - 2 years ago

Prime Medicine Receives Up to $15 Million from Cystic Fibrosis Foundation to Advance Hotspot and PASSIGE™ Prime Editors for Cystic Fibrosis

Cystic Fibrosis Foundation Funds Up to $15 Million to Prime Medicine to Pursue Gene Editing in CF

Jan 25, 2024, 8:00 AM EST - 2 years ago

Cystic Fibrosis Foundation Funds Up to $15 Million to Prime Medicine to Pursue Gene Editing in CF

Prime Medicine Transcript: J.P. Morgan 42nd Annual Healthcare Conference 2024

Jan 8, 2024, 5:15 PM EST - 2 years ago

Prime Medicine Transcript: J.P. Morgan 42nd Annual Healthcare Conference 2024

Prime Medicine Slides: FY 2024

Jan 8, 2024, 5:15 PM EST - 2 years ago

Prime Medicine Slides: FY 2024

Prime Medicine Appoints Allan Reine, M.D., as Chief Financial Officer

Jan 5, 2024, 8:00 AM EST - 2 years ago

Prime Medicine Appoints Allan Reine, M.D., as Chief Financial Officer

Prime Medicine to Present at 42nd Annual J.P. Morgan Healthcare Conference

Jan 2, 2024, 8:00 AM EST - 2 years ago

Prime Medicine to Present at 42nd Annual J.P. Morgan Healthcare Conference

Prime Medicine Transcript: 14th Annual Jefferies London Healthcare Conference 2023

Nov 16, 2023, 8:30 AM EST - 2 years ago

Prime Medicine Transcript: 14th Annual Jefferies London Healthcare Conference 2023

Prime Medicine Transcript: Stifel 2023 Annual Healthcare Conference

Nov 14, 2023, 4:10 PM EST - 3 years ago

Prime Medicine Transcript: Stifel 2023 Annual Healthcare Conference

Prime Medicine to Present at Upcoming Investor Conferences

Nov 8, 2023, 8:00 AM EST - 3 years ago

Prime Medicine to Present at Upcoming Investor Conferences

Prime Medicine Reports Third Quarter 2023 Financial Results and Provides Business Updates

Nov 3, 2023, 4:01 PM EDT - 3 years ago

Prime Medicine Reports Third Quarter 2023 Financial Results and Provides Business Updates

Prime Medicine Quarterly report: Q3 2023

Nov 3, 2023, 8:00 AM EDT - 3 years ago

Prime Medicine Quarterly report: Q3 2023

Prime Medicine Earnings release: Q3 2023

Nov 3, 2023, 8:00 AM EDT - 3 years ago

Prime Medicine Earnings release: Q3 2023

Prime Medicine Registration statement: Registration Filing

Nov 3, 2023, 8:00 AM EDT - 3 years ago

Prime Medicine Registration statement: Registration Filing

Prime Medicine Presents First-ever Prime Editing Data in Non-human Primates Demonstrating Highly Efficient Ability of Prime Editors to Precisely Correct Disease-causing Mutation of GSD1b

Oct 27, 2023, 6:00 AM EDT - 3 years ago

Prime Medicine Presents First-ever Prime Editing Data in Non-human Primates Demonstrating Highly Efficient Ability of Prime Editors to Precisely Correct Disease-causing Mutation of GSD1b

USAEquityResearch
USAEquityResearch Aug. 18 at 10:32 PM
$PRME 📊 USAEquityResearch ▼ 3.05 (-3.79%) Trend: Bearish 📉 RSI (14): 50.8 — neutral territory MACD: bullish, above signal line and rising Volume: below average 📌 Key Levels Resistance: 3.26 Support: 2.81 20-MA: 3.05 | 50-MA: 3.26 Educational content only. Not financial advice.
0 · Reply
notreload_ai
notreload_ai Aug. 18 at 9:00 PM
BMO initiates $PRME at Outperform/$9, citing its unique prime-editing tech that delivers precise DNA fixes without double-strand breaks. https://notreload.xyz/xy/bmo-outperform-on-prme-for-differentiated-gene-editing/
1 · Reply
Toro_of_Ga
Toro_of_Ga Aug. 17 at 3:16 PM
$PRME lets go..
0 · Reply
Patrick0423
Patrick0423 Aug. 17 at 12:32 PM
$PRME How’s this? I heard someone recommend him at a high-end dinner.
1 · Reply
veryboredXYZ
veryboredXYZ Aug. 15 at 12:39 AM
$PRME buying zone, stay like that til Monday pls
0 · Reply
DOGBIRD
DOGBIRD Aug. 14 at 6:11 PM
$PRME Surprise us with a deal. Solve the cash concerns. It'll pop like a slingshot.
0 · Reply
AcceleratorModel
AcceleratorModel Aug. 14 at 4:28 PM
$PRME time cmon !
0 · Reply
PorkchopSquats
PorkchopSquats Aug. 14 at 2:22 PM
$PRME
0 · Reply
BIOTECH_GURU
BIOTECH_GURU Aug. 14 at 11:01 AM
$PRME They own patent for genetic editing technology that is proven on the benchtop and now has human data to support it. Best case scenario, adoption of multiple genetic conditions to include common diseases like hyperlipidemia with pcsk9 gene deletion, with no live failure signal. This would move from a rare disease TAM to a cardiovascular disease prevention/treatment TAM. This would become instantly $20B acquisition target. Worst case scenario: they get bought out for a cheap price prior to recognition of potention just like $VERV Timwline 12-24 months. Nfa. Gltya.
0 · Reply
DOGBIRD
DOGBIRD Aug. 13 at 4:39 PM
$PRME Curious if Optiprime will open more doors for deals near term.
0 · Reply
rweb
rweb Aug. 13 at 3:55 PM
$PRME is this thing alive?
0 · Reply
Quantumup
Quantumup Aug. 12 at 4:48 PM
Raymond James reiterated $MNPR Outperform-$123 and said -- We continue to model ALXN1840 approval and launch in 2027—Remain Outperform rated on MNPR shares following 2Q26 update. $RARE $PRME ETON Vivet Therapeutics - PFE AZN TELO Orphalan Raymond James added—All eyes remain focused on the rolling NDA submission for ALXN1840 in Wilson disease, which was recently initiated in July and the company expects to complete in the coming months. Recall, this allows FDA to receive and begin reviewing specific application sections as they are submitted, but acceptance of the application and PDUFA date assignment cannot occur until the application is complete and fully received. ALXN1840 does have Fast Track designation, which could lead to a shorter review time once the application is complete. We continue to model ALXN1840 approval and launch in 2027.
0 · Reply
ATTAB0Y
ATTAB0Y Aug. 12 at 4:44 PM
$PRME USPTO publishes Prime Medicine’s cystic fibrosis prime editing application.
0 · Reply
Knowwtuown
Knowwtuown Aug. 12 at 4:43 PM
$PRME OptiPrime showed extremely encouraging possibilities with the CF program. Probably not going to move the stock much, but this Scientific Development could have a profound impact on Prime. “OptiPrime doubled F508del correction from 11% to 22% after testing only eight AI-selected guides—an optimization that previously took years.” That suggests Prime’s CF program could move faster and require substantially less laboratory screening. But the remaining decisive hurdle is ReCode’s ability to deliver the editor efficiently throughout human airway tissue.
0 · Reply
DOGBIRD
DOGBIRD Aug. 12 at 4:25 PM
$PRME Before OptiPrime: DNA target → design lots of pegRNAs → test them experimentally → find one that works With OptiPrime: DNA target → OptiPrime predicts/designs promising pegRNAs → test the best candidates → much faster optimization So basically AI optimization layer for prime editing that'll cut cost & time?
0 · Reply
ATTAB0Y
ATTAB0Y Aug. 12 at 3:56 PM
$PRME
1 · Reply
ATTAB0Y
ATTAB0Y Aug. 12 at 3:52 PM
$PRME OptiPrime
0 · Reply
jschor88
jschor88 Aug. 12 at 2:52 PM
$PRME 🚀
0 · Reply
PorkchopSquats
PorkchopSquats Aug. 11 at 10:40 PM
$PRME She’s a grower not a shower.
0 · Reply
LadsAndGents
LadsAndGents Aug. 11 at 5:19 PM
$PRME yay.. 3.60s on the cards
1 · Reply
DOGBIRD
DOGBIRD Aug. 11 at 5:13 PM
$PRME Patiently holding what I already have. Will gladly add more lower or higher once theres some clarity on cash runway.
0 · Reply
Knowwtuown
Knowwtuown Aug. 11 at 5:12 PM
$PRME the most important player at Prime today may be the CFO, Svetlana Makhni. She was also given the responsibility of Corporate Development. If you look at her background she isn’t just a “bean counter”, she is a dealmaker. She did time at Goldman, BMO and Blackstone.
4 · Reply